TMEM108
geneOn this page
Also known as MGC3040CT124
Summary
TMEM108 (transmembrane protein 108, HGNC:28451) is a protein-coding gene on chromosome 3q22.1, encoding Transmembrane protein 108 (Q6UXF1). Transmembrane protein required for proper cognitive functions.
Predicted to be involved in several processes, including cellular response to brain-derived neurotrophic factor stimulus; nervous system development; and regulation of signal transduction. Predicted to be located in somatodendritic compartment. Predicted to be active in several cellular components, including endosome; glutamatergic synapse; and postsynaptic density membrane.
Source: NCBI Gene 66000 — RefSeq curated summary.
At a glance
- GWAS associations: 17
- Clinical variants (ClinVar): 16 total
- MANE Select transcript:
NM_023943
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:28451 |
| Approved symbol | TMEM108 |
| Name | transmembrane protein 108 |
| Location | 3q22.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | MGC3040, CT124 |
| Ensembl gene | ENSG00000144868 |
| Ensembl biotype | protein_coding |
| OMIM | 617361 |
| Entrez | 66000 |
Gene structure
Transcript identifiers
Ensembl transcripts: 25 — 23 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined
ENST00000321871, ENST00000393130, ENST00000508711, ENST00000510183, ENST00000511388, ENST00000511555, ENST00000512137, ENST00000512662, ENST00000514529, ENST00000514894, ENST00000515826, ENST00000930512, ENST00000930513, ENST00000930514, ENST00000930515, ENST00000930516, ENST00000930517, ENST00000930518, ENST00000930519, ENST00000930520, ENST00000968854, ENST00000968855, ENST00000968856, ENST00000968857, ENST00000968858
RefSeq mRNA: 3 — MANE Select: NM_023943
NM_001136469, NM_001282865, NM_023943
CCDS: CCDS33858, CCDS75012
Canonical transcript exons
ENST00000321871 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001223724 | 133379752 | 133381161 |
| ENSE00001363298 | 133038391 | 133038435 |
| ENSE00001495835 | 133045902 | 133046020 |
| ENSE00002059602 | 133395864 | 133397775 |
| ENSE00003542740 | 133390180 | 133390334 |
| ENSE00003560653 | 133229266 | 133229351 |
Expression profiles
Bgee: expression breadth ubiquitous, 206 present calls, max score 98.42.
FANTOM5 (CAGE): breadth broad, TPM avg 5.0854 / max 393.0664, expressed in 621 samples.
FANTOM5 promoters (5 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 38644 | 2.6678 | 507 |
| 38643 | 1.7058 | 441 |
| 38642 | 0.3169 | 193 |
| 38645 | 0.3110 | 91 |
| 38646 | 0.0839 | 56 |
Top tissues by expression
244 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| cortical plate | UBERON:0005343 | 98.42 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 92.87 | gold quality |
| ganglionic eminence | UBERON:0004023 | 92.52 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 91.95 | gold quality |
| ventricular zone | UBERON:0003053 | 91.34 | gold quality |
| endothelial cell | CL:0000115 | 89.96 | gold quality |
| biceps brachii | UBERON:0001507 | 89.72 | gold quality |
| vastus lateralis | UBERON:0001379 | 89.42 | gold quality |
| skeletal muscle tissue of biceps brachii | UBERON:0004502 | 88.45 | gold quality |
| quadriceps femoris | UBERON:0001377 | 87.50 | silver quality |
| skeletal muscle tissue | UBERON:0001134 | 86.60 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 86.29 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 86.07 | gold quality |
| entorhinal cortex | UBERON:0002728 | 85.85 | gold quality |
| decidua | UBERON:0002450 | 85.76 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 85.68 | gold quality |
| secondary oocyte | CL:0000655 | 85.48 | gold quality |
| muscle tissue | UBERON:0002385 | 85.22 | gold quality |
| lateral nuclear group of thalamus | UBERON:0002736 | 84.86 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 84.79 | gold quality |
| primary visual cortex | UBERON:0002436 | 83.68 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 83.40 | gold quality |
| right testis | UBERON:0004534 | 83.07 | gold quality |
| right adrenal gland | UBERON:0001233 | 82.88 | gold quality |
| left testis | UBERON:0004533 | 82.75 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 82.68 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 82.45 | gold quality |
| left adrenal gland | UBERON:0001234 | 82.28 | gold quality |
| postcentral gyrus | UBERON:0002581 | 82.28 | gold quality |
| neocortex | UBERON:0001950 | 82.16 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-HCAD-35 | yes | 89.64 |
| E-ANND-3 | yes | 4.97 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
111 targeting TMEM108, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-3924 | 100.00 | 72.09 | 2394 |
| HSA-MIR-656-3P | 100.00 | 72.15 | 2788 |
| HSA-MIR-5692B | 100.00 | 71.32 | 2622 |
| HSA-MIR-5692C | 100.00 | 71.32 | 2622 |
| HSA-MIR-8485 | 100.00 | 77.57 | 4731 |
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-1277-5P | 100.00 | 73.95 | 5056 |
| HSA-MIR-6748-5P | 100.00 | 65.81 | 1057 |
| HSA-MIR-432-3P | 100.00 | 67.86 | 705 |
| HSA-MIR-340-5P | 100.00 | 72.50 | 4437 |
| HSA-MIR-7110-3P | 100.00 | 73.18 | 2486 |
| HSA-MIR-6759-5P | 99.99 | 66.54 | 785 |
| HSA-MIR-150-5P | 99.99 | 66.69 | 1976 |
| HSA-MIR-196A-1-3P | 99.99 | 72.15 | 2772 |
| HSA-MIR-539-3P | 99.98 | 70.74 | 1616 |
| HSA-MIR-485-3P | 99.98 | 70.68 | 1585 |
| HSA-MIR-568 | 99.98 | 69.86 | 2084 |
| HSA-MIR-4803 | 99.98 | 71.99 | 3117 |
| HSA-MIR-3148 | 99.97 | 75.06 | 6478 |
| HSA-MIR-6793-5P | 99.97 | 65.95 | 758 |
| HSA-MIR-548AN | 99.97 | 70.91 | 2817 |
| HSA-MIR-651-3P | 99.94 | 73.48 | 5177 |
| HSA-MIR-374A-5P | 99.90 | 71.34 | 2923 |
| HSA-MIR-374B-5P | 99.90 | 69.98 | 2734 |
| HSA-MIR-3686 | 99.90 | 70.53 | 2432 |
| HSA-MIR-4493 | 99.90 | 66.48 | 977 |
| HSA-MIR-4496 | 99.88 | 68.89 | 2236 |
| HSA-MIR-3941 | 99.86 | 70.54 | 2735 |
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | tmem108 | ENSDARG00000090230 |
| mus_musculus | Tmem108 | ENSMUSG00000042757 |
| rattus_norvegicus | Tmem108 | ENSRNOG00000010911 |
Protein
Protein identifiers
Transmembrane protein 108 — Q6UXF1 (reviewed: Q6UXF1)
Alternative names: Retrolinkin
All UniProt accessions (8): Q6UXF1, B3KT64, D6R911, D6R9I6, D6RFH6, D6RGJ9, D6RIE1, E9PB58
UniProt curated annotations — full annotation on UniProt →
Function. Transmembrane protein required for proper cognitive functions. Involved in the development of dentate gyrus (DG) neuron circuitry, is necessary for AMPA receptors surface expression and proper excitatory postsynaptic currents of DG granule neurons. Regulates the organization and stability of the microtubule network of sensory neurons to allow axonal transport. Through the interaction with DST, mediates the docking of the dynein/dynactin motor complex to vesicle cargos for retrograde axonal transport. In hippocampal neurons, required for BDNF-dependent dendrite outgrowth. Cooperates with SH3GL2 and recruits the WAVE1 complex to facilitate actin-dependent BDNF:NTRK2 early endocytic trafficking and mediate signaling from early endosomes.
Subunit / interactions. Interacts with DST (isoform 1). Interacts with SH3GL2. Interacts (via N-terminus) with CYFIP1 and CYFIP2; the interactions associate TMEM108 with the WAVE1 complex.
Subcellular location. Membrane. Postsynaptic density. Endosome membrane. Cell projection. Axon. Dendrite. Early endosome.
Post-translational modifications. Glycosylated.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q6UXF1-1 | 1 | yes |
| Q6UXF1-2 | 2 |
RefSeq proteins (3): NP_001129941, NP_001269794, NP_076432* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR031508 | TMEM108 | Family |
Pfam: PF15759
UniProt features (19 total): compositionally biased region 8, region of interest 4, transmembrane region 2, splice variant 2, chain 1, sequence variant 1, sequence conflict 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q6UXF1-F1 | 45.75 | 0.00 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 244 (showing top):
GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, E2F_Q4, GOBP_DENTATE_GYRUS_DEVELOPMENT, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_AXO_DENDRITIC_TRANSPORT, GOBP_NEURON_PROJECTION_EXTENSION, E2F4DP1_01, GOBP_GROWTH, TATTATA_MIR374, GOBP_NEUROGENESIS, GOBP_VESICLE_MEDIATED_TRANSPORT, USF_C, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, GOBP_FOREBRAIN_DEVELOPMENT, GOBP_CELL_CELL_SIGNALING
GO Biological Process (10): receptor-mediated endocytosis (GO:0006898), retrograde axonal transport (GO:0008090), dentate gyrus development (GO:0021542), neuron projection development (GO:0031175), positive regulation of neurotrophin TRK receptor signaling pathway (GO:0051388), postsynaptic density organization (GO:0097106), dendrite extension (GO:0097484), regulation of neurotransmitter receptor localization to postsynaptic specialization membrane (GO:0098696), modulation of excitatory postsynaptic potential (GO:0098815), cellular response to brain-derived neurotrophic factor stimulus (GO:1990416)
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (13): early endosome (GO:0005769), endosome membrane (GO:0010008), postsynaptic density (GO:0014069), axon (GO:0030424), dendrite (GO:0030425), somatodendritic compartment (GO:0036477), postsynaptic density membrane (GO:0098839), glutamatergic synapse (GO:0098978), axon cytoplasm (GO:1904115), endosome (GO:0005768), membrane (GO:0016020), cell projection (GO:0042995), synapse (GO:0045202)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| endosome | 2 |
| neuron projection | 2 |
| endocytosis | 1 |
| axonal transport | 1 |
| axon cytoplasm | 1 |
| hippocampus development | 1 |
| anatomical structure development | 1 |
| neuron development | 1 |
| plasma membrane bounded cell projection organization | 1 |
| positive regulation of signal transduction | 1 |
| neurotrophin TRK receptor signaling pathway | 1 |
| regulation of neurotrophin TRK receptor signaling pathway | 1 |
| postsynaptic specialization organization | 1 |
| neuron projection extension | 1 |
| regulation of biological quality | 1 |
| neurotransmitter receptor localization to postsynaptic specialization membrane | 1 |
| regulation of protein localization to synapse | 1 |
| regulation of receptor localization to synapse | 1 |
| regulation of protein localization to cell periphery | 1 |
| regulation of protein localization to membrane | 1 |
| regulation of signal transduction | 1 |
| regulation of nervous system process | 1 |
| regulation of membrane potential | 1 |
| modulation of chemical synaptic transmission | 1 |
| excitatory postsynaptic potential | 1 |
| cellular response to nerve growth factor stimulus | 1 |
| binding | 1 |
| cytoplasmic vesicle membrane | 1 |
| bounding membrane of organelle | 1 |
| asymmetric synapse | 1 |
| postsynaptic specialization | 1 |
| dendritic tree | 1 |
| postsynaptic density | 1 |
| postsynaptic membrane | 1 |
| postsynaptic specialization membrane | 1 |
| synapse | 1 |
| axon | 1 |
| neuron projection cytoplasm | 1 |
| endomembrane system | 1 |
Protein interactions and networks
STRING
494 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TMEM108 | SH3GL2 | Q99962 | 792 |
| TMEM108 | DST | Q03001 | 695 |
| TMEM108 | DYNC1H1 | Q14204 | 690 |
| TMEM108 | DCTN1 | Q14203 | 655 |
| TMEM108 | DLX3 | O60479 | 547 |
| TMEM108 | GAS2 | O43903 | 521 |
| TMEM108 | MSX2 | P35548 | 514 |
| TMEM108 | SYNDIG1L | A6NDD5 | 489 |
| TMEM108 | CDV3 | Q9UKY7 | 453 |
| TMEM108 | Q3SXR2 | Q3SXR2 | 435 |
| TMEM108 | WDR64 | B1ANS9 | 430 |
| TMEM108 | SYNDIG1 | Q9H7V2 | 426 |
| TMEM108 | DLX5 | P56178 | 424 |
| TMEM108 | TBX6 | O95947 | 397 |
| TMEM108 | RYK | P34925 | 389 |
IntAct
15 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| TMEM108 | FKBP7 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM108 | SGTB | psi-mi:“MI:0915”(physical association) | 0.560 |
| FHL3 | TMEM108 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TMEM108 | TCAF2 | psi-mi:“MI:0914”(association) | 0.530 |
| TMEM108 | ANXA7 | psi-mi:“MI:0915”(physical association) | 0.370 |
| TMEM108 | ARHGEF6 | psi-mi:“MI:0915”(physical association) | 0.370 |
| TMEM108 | SH3GL2 | psi-mi:“MI:0915”(physical association) | 0.370 |
| TMEM108 | FHL3 | psi-mi:“MI:0915”(physical association) | 0.000 |
| FKBP7 | TMEM108 | psi-mi:“MI:0915”(physical association) | 0.000 |
| TMEM108 | SGTB | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (49): TMEM108 (Reconstituted Complex), RRN3 (Affinity Capture-MS), FAM115C (Affinity Capture-MS), POU2F2 (Affinity Capture-MS), SLC25A24 (Affinity Capture-MS), MTFP1 (Affinity Capture-MS), SLC25A23 (Affinity Capture-MS), SFXN5 (Affinity Capture-MS), PDXDC1 (Affinity Capture-MS), TUBB3 (Affinity Capture-MS), TUBA4A (Affinity Capture-MS), KNTC1 (Affinity Capture-MS), METAP2 (Affinity Capture-MS), ACAD10 (Affinity Capture-MS), BRAT1 (Affinity Capture-MS)
ESM2 similar proteins: A0A2R8Y7Y5, A1KXC4, A6QLF8, J3KML8, O00592, O35188, O55145, O57604, P06484, P07141, P13838, P14220, P15702, P16150, P18827, P20934, P26260, P34740, P47951, P59647, P78423, P97808, Q08DZ5, Q1ECS6, Q28270, Q28645, Q29RT9, Q3MIW9, Q3TNW5, Q52S86, Q58Y74, Q5RAF8, Q62170, Q64314, Q6MG22, Q6P9X9, Q6UWI2, Q6UXF1, Q86YL7, Q8BHE4
Diamond homologs: A6QLF8, Q6UXF1, Q8BHE4
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
16 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 10 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
4053 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 3:133038433:GAG:G | donor_gain | 1.0000 |
| 3:133038436:G:GG | donor_gain | 1.0000 |
| 3:133038437:T:G | donor_loss | 1.0000 |
| 3:133041783:T:G | acceptor_gain | 1.0000 |
| 3:133229264:A:AG | acceptor_gain | 1.0000 |
| 3:133229265:G:GG | acceptor_gain | 1.0000 |
| 3:133229265:GAC:G | acceptor_gain | 1.0000 |
| 3:133229265:GACA:G | acceptor_gain | 1.0000 |
| 3:133229347:GTTAA:G | donor_gain | 1.0000 |
| 3:133229348:T:G | donor_gain | 1.0000 |
| 3:133229348:TTAA:T | donor_gain | 1.0000 |
| 3:133229351:AG:A | donor_loss | 1.0000 |
| 3:133229352:G:C | donor_loss | 1.0000 |
| 3:133229352:G:GG | donor_gain | 1.0000 |
| 3:133229353:TAA:T | donor_loss | 1.0000 |
| 3:133381159:GCT:G | donor_gain | 1.0000 |
| 3:133381162:G:GG | donor_gain | 1.0000 |
| 3:133390178:A:AG | acceptor_gain | 1.0000 |
| 3:133390179:G:GA | acceptor_gain | 1.0000 |
| 3:133390179:GC:G | acceptor_gain | 1.0000 |
| 3:133390179:GCT:G | acceptor_gain | 1.0000 |
| 3:133390179:GCTGT:G | acceptor_gain | 1.0000 |
| 3:133390332:GAGGT:G | donor_loss | 1.0000 |
| 3:133390333:AGGTA:A | donor_loss | 1.0000 |
| 3:133390335:GT:G | donor_loss | 1.0000 |
| 3:133390336:T:A | donor_loss | 1.0000 |
| 3:133045900:A:AG | acceptor_gain | 0.9900 |
| 3:133045900:AGTT:A | acceptor_gain | 0.9900 |
| 3:133045901:G:GG | acceptor_gain | 0.9900 |
| 3:133045901:GTTG:G | acceptor_gain | 0.9900 |
AlphaMissense
3664 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 3:133381140:A:C | S477R | 0.999 |
| 3:133381142:C:A | S477R | 0.999 |
| 3:133381142:C:G | S477R | 0.999 |
| 3:133390278:T:C | F517L | 0.997 |
| 3:133390280:C:A | F517L | 0.997 |
| 3:133390280:C:G | F517L | 0.997 |
| 3:133395936:T:C | F560L | 0.997 |
| 3:133395938:C:A | F560L | 0.997 |
| 3:133395938:C:G | F560L | 0.997 |
| 3:133395954:T:C | F566L | 0.997 |
| 3:133395956:T:A | F566L | 0.997 |
| 3:133395956:T:G | F566L | 0.997 |
| 3:133381147:C:G | P479R | 0.996 |
| 3:133390253:G:C | W508C | 0.996 |
| 3:133390253:G:T | W508C | 0.996 |
| 3:133390279:T:C | F517S | 0.996 |
| 3:133395932:C:A | N558K | 0.996 |
| 3:133395932:C:G | N558K | 0.996 |
| 3:133390183:T:A | V485D | 0.995 |
| 3:133395955:T:G | F566C | 0.995 |
| 3:133390279:T:G | F517C | 0.994 |
| 3:133395925:T:C | L556P | 0.994 |
| 3:133395937:T:G | F560C | 0.994 |
| 3:133395946:A:T | E563V | 0.994 |
| 3:133381147:C:A | P479H | 0.993 |
| 3:133381158:T:C | C483R | 0.993 |
| 3:133395928:T:A | V557D | 0.993 |
| 3:133380997:T:G | F429C | 0.992 |
| 3:133381122:T:A | W471R | 0.992 |
| 3:133381122:T:C | W471R | 0.992 |
dbSNP variants (sampled 300 via entrez): RS1000018591 (3:133178063 A>G), RS1000032053 (3:133146693 G>A), RS1000051906 (3:133339237 A>G), RS1000069744 (3:133045929 A>T), RS1000070370 (3:133089513 CAT>C), RS1000076805 (3:133290454 C>T), RS1000085751 (3:133213365 C>T), RS1000088785 (3:133097097 G>T), RS1000117428 (3:133073502 CTCTCTCTCTATATATA>C), RS1000120477 (3:133220393 C>T), RS1000126697 (3:133096553 T>C), RS1000127087 (3:133140161 G>T), RS1000145520 (3:133239999 G>A), RS1000149361 (3:133190046 T>C), RS1000153731 (3:133082665 G>C)
Disease associations
OMIM: gene MIM:617361 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
17 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000880_27 | Menarche (age at onset) | 1.000000e-08 |
| GCST001303_7 | IgE grass sensitization | 3.000000e-06 |
| GCST003993_15 | Menarche (age at onset) | 4.000000e-06 |
| GCST004571_3 | Iron status biomarkers (total iron binding capacity) | 4.000000e-08 |
| GCST004571_6 | Iron status biomarkers (total iron binding capacity) | 1.000000e-08 |
| GCST004572_13 | Iron status biomarkers (transferrin saturation) | 4.000000e-08 |
| GCST004572_16 | Iron status biomarkers (transferrin saturation) | 1.000000e-08 |
| GCST006624_1 | Systolic blood pressure | 2.000000e-11 |
| GCST007267_106 | Systolic blood pressure | 2.000000e-11 |
| GCST007576_81 | Chronotype | 4.000000e-11 |
| GCST008151_58 | Waist circumference | 8.000000e-06 |
| GCST008160_17 | Waist circumference | 8.000000e-06 |
| GCST011101_1 | Bipolar disorder | 2.000000e-08 |
| GCST011176_24 | Stroke | 6.000000e-08 |
| GCST011494_8 | Daytime nap | 1.000000e-09 |
| GCST011823_9 | Parkinson’s disease progression (cognitive) | 2.000000e-08 |
| GCST012490_257 | Femur bone mineral density x serum urate levels interaction | 1.000000e-08 |
EFO canonical traits (7, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004703 | age at menarche |
| EFO:0006334 | total iron binding capacity |
| EFO:0006335 | systolic blood pressure |
| EFO:0008328 | chronotype measurement |
| EFO:0007828 | daytime rest measurement |
| EFO:0008336 | disease progression measurement |
| EFO:0004531 | urate measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
25 total (human), top 25 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects expression, decreases methylation, increases expression | 6 |
| Phenylmercuric Acetate | affects cotreatment, decreases expression | 2 |
| p-Chloromercuribenzoic Acid | affects cotreatment, decreases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| methylmercuric chloride | decreases expression | 1 |
| propionaldehyde | increases expression | 1 |
| sodium arsenite | decreases expression, increases abundance | 1 |
| butyraldehyde | increases expression | 1 |
| pentanal | increases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, decreases expression | 1 |
| dorsomorphin | affects cotreatment, decreases expression | 1 |
| bisphenol S | affects cotreatment, decreases methylation | 1 |
| Temozolomide | decreases expression | 1 |
| Sunitinib | increases expression | 1 |
| Fulvestrant | affects cotreatment, decreases methylation | 1 |
| Aldehydes | increases expression | 1 |
| Arsenic | decreases expression, increases abundance | 1 |
| Atrazine | decreases expression | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Tobacco Smoke Pollution | increases methylation | 1 |
| Tretinoin | decreases expression | 1 |
| Triclosan | increases expression | 1 |
| Tunicamycin | decreases expression | 1 |
| Antirheumatic Agents | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): seasonal allergic rhinitis, stroke disorder